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Background: Work-related asthma (WRA) is a major cause of respiratory disease in modern societies. The diagnosis
and consequently an opportunity for prevention are often missed in practice.
Methods: Based on recent studies and systematic reviews of the literature methods for detection of WRA and
identification of specific causes of allergic WRA are discussed.
Results and Conclusions: All workers should be asked whether symptoms improve on days away from work or on
holidays. Positive answers should lead to further investigation. Spirometry and non-specific bronchial responsiveness
should be measured, but carefully performed and validly analysed serial peak expiratory flow or forced expiratory
volume in one second (FEV1) measurements are more specific and confirm occupational asthma in about 82% of
those still exposed to the causative agent. Skin prick testing or specific immunoglobulin E assays are useful to
document allergy to high molecular weight allergens. Specific inhalational challenge tests come closest to a gold
standard test, but lack standardisation, availability and sensitivity. Supervised workplace challenges can be used
when specific challenges are unavailable or the results non-diagnostic, but methodology lacks standardisation.
Finally, if the diagnosis remains unclear a follow-up with serial measurements of FEV1 and non-specific bronchial
hyperresponsiveness should detect those likely to develop permanent impairment from their occupational
exposures.
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At least 15% of adult asthma is induced or triggered by
factors in the workplace [1]. Early diagnosis can improve
the prognosis of work-related asthma since cessation of
exposure after appearance of asthmatic symptoms and
identification of specific sensitization within the first
months after onset of symptoms, may permit a full re-
covery. In addition, diagnosis of a case of work-related
asthma (WRA) is a sentinel event that should lead to ef-
fective primary preventive measures in the individual
workplace or in a branch of industry [2-4]. The reader is
referred to recent comprehensive and systematic litera-
ture reviews [5-11]. Diagnosis of work-related asthma is
in many cases a complex undertaking consisting of vari-
ous diagnostic tests and procedures. The main object of* Correspondence: tor.aasen@helse-bergen.no
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reproduction in any medium, provided the ordiagnosis is to identify the cause of the asthma, in par-
ticular to separate occupational asthma from asthma un-
related to work, assisting decisions about intervention to
prevent further exposure to the patient and is also im-
portant for handling compensation claims. The possibil-
ities for prevention and degree of economic support for
the patients may differ between industries and countries.
The optimal diagnostic strategy will vary depending on
medical as well as economic and juridical evidence.
Obvious preconditions for considering a diagnosis of
WRA are typical diagnostic findings of asthma (see below)
and an association of asthma symptoms with exposure at
work. Asthma present before occupational exposure but
associated with worsening at the start of a new occupa-
tional exposure indicates a diagnosis of work-aggravated
asthma (WAA). Asthma relapsing or becoming more se-
vere some time after exposure to a new occupational aller-
gen may be due to occupational asthma, and does nottd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tional history should be obtained in all cases [12,13].
The diagnosis of WRA can be performed in three
steps:
1. Making the diagnosis of asthma.
Asthma diagnosis is performed according to recent
international guidelines [14,15]. However, the
diagnosis of asthma is not always straightforward.
Asthma is a heterogeneous disease, and the
diagnostic criteria are ill-defined and vary between
studies [16,17]. Further, there is considerable overlap
between asthma and chronic obstructive pulmonary
disease (COPD) [18]. A doctor’s diagnosis of asthma
may be frequently questionable [19].
2. Identification of the workplace as the cause of the
patient’s asthma.
Objective verification of the association between
work exposure and airflow limitation is a basis for
diagnosing WRA, both for new onset occupational
asthma (OA) and WAA.
3. Identification of a specific agent causing WRA.
This step is most demanding on resources. A
specific diagnosis is needed before appropriate
remedial action can be taken in the workplace, but
the full diagnostic armamentarium is only available
at few centres worldwide [20]. The extent of
diagnostic investigation will depend on what
resources are available and on a decision analysis
that takes into account the consequences of false
positive and false negative diagnoses [21].
Diagnosis of allergic work-related asthma
Recognized exposure to a known allergen at work and a
provisional diagnosis of WRA should lead to an exten-
sive diagnostic work-up to identify the agent and object-
ively confirm its causal role. Occupational allergens
conform to the general definition of allergens [22].
To reach the diagnosis of WRA several pieces of evi-
dence are necessary:
 Objective information of exposure to known
sensitizers.
 Demonstration of an association between exposure
at work and airflow limitation by lung function
testing or changes in non-specific bronchial
hyperresponsiveness (NSBHR) or changes of airway
inflammation (e.g. sputum eosinophils).
 Identification of a specific allergic reaction to the
occupational agent (rather than an acute irritant
reaction).
Note: There are many OA-inducing agents and
worksites generally included in the lists of airwayallergens and irritants (for details see latest summaries
[23,24] and Irritants: Evidence table of reporting OA or
occupational COPD due to irritants (Authors: X. Baur,
P. Bakehe, H. Vellguth, JOMT), ACGIH Tables: Occupa-
tional agents with respiratory effects according to
ACGIH and/or classified with the H334 (R42) phrase
and/or H335 (R37) phrase plus EU regulations (Author:
X. Baur); however, due to negative allergological findings
for many of them pathogenetic mechanisms are still un-
known; examples include most cases of isocyanate and
potroom asthma [25].
Diagnostic tests can be divided into those which
should be available to all respiratory physicians and
those generally confined to specialist in occupational
lung diseases.
Diagnostic methods suitable for all respiratory and
occupational physicians
All working patients with asthma and COPD should be
asked whether their symptoms improve on days away
from work or on holidays. Further investigation is re-
quired for all positive respondents.
Questionnaires. Questionnaires are extensively used
as screening tools in epidemiological studies. Several epi-
demiological questionnaires are in current use [26-28].
Questions about work exposure and association of
symptoms to work may be used in clinical diagnosis.In
the clinical setting questionnaires that identify symptoms
of wheeze and/or shortness of breath which improve on
days away from work or on holiday have a high sensitiv-
ity, but relatively low specificity for OA [28-34].
Medical histories by experts. There is general agree-
ment that medical histories taken by experts have high sen-
sitivity, but their specificity may be lower [28,29,32,35-38].
Exposure assessment [39]. This comes both within
the compass of a generalist and a specialist. A generalist
should elicit exposures in high-risk occupations, in
which asthma should be assumed to be occupational un-
less excluded by objective tests. The workers reported
from population studies to be at increased risk of devel-
oping asthma include; bakers, chemical workers, cleaners,
cooks, electrical and electronic production workers, farm
workers, food processors, forestry workers, healthcare
workers, laboratory technicians, mechanics, metal workers,
painters, plastics and rubber workers, storage workers, tex-
tile workers, waiters, welders and wood workers. A special-
ist should identify specific exposures, with a systematic
occupational history, scrutiny of exposure documenta-
tion such as material safety data sheets (MSDSs), in-
ternal reports and industrial hygiene measurements
from the industry. The failure to find a sensitiser on a
MSDS should not preclude the diagnosis of occupational
asthma, as many sensitisers are not regularly listed, par-
ticularly those in low concentration, those that are only
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and those given non-specific titles such as preservative,
biocide, fragrance, resin etc.
Spirometry [40,41]. Spirometry is required in all pa-
tients considered for WRA. It is used as a main instru-
ment for monitoring lung function longitudinally during
surveillance, also during measurement of non-specific
bronchial hyperresponsiveness (NSBHR) and in specific
inhalation challenge. Many workers with WRA have
normal spirometry when seen in a clinic. There is also a
role for measurement of airway resistance or specific
conductance to monitor lung function when a patient
cannot record FEV1 reliably.
Pre- to post-shift changes in lung function cannot
be recommended for the validation or exclusion of
WRA [42,43]. Serial PEF and spirometry measurements
have been shown to be superior to cross-shift change in
diagnosing WRA [43].
Measurement of non-specific airway responsiveness
[44,45]. Challenge with methacholine is part of the initial
diagnostic work-up. It can also be measured before and
after a period of work exposure and during SIC. Normal
NSBHR does not exclude OA.A large number of con-
cordant studies from different centres using different
methodologies demonstrated that increased NSBHR is
often found in workers with WRA. There are, however,
many reports of normal methacholine or histamine re-
activity within 24 hours of exposure in workers with
confirmed OA [28,29,32,34,36,38,46-57].
Serial lung function testing. If clinical OA exists, ex-
posure to routine levels of the causative agent should re-
sult in a measureable decline in lung function in the
hours after exposure. This is usually performed by a sim-
ple expiratory peak flow (PEF) meter or by a portable
spirometer [58]. Measuring PEF or FEV1 during periods
of work and away from work may document a causal re-
lationship between exposure and airflow reduction [58].
Technical issues related to interpretation have been ex-
tensively studied [59]. The frequency and duration of the
recording depends on the method of analysis, but in
general, at least 4 readings/day are required, although 8
readings a day allows shorter records, with usual expos-
ure on work days and no changes in treatment on days
away from work. A 3-week record containing at least 3
periods off work would be suitable for most forms of
analysis [60-62]. The sensitivity and specificity of serial
peak flow measurements performed after extensive instruc-
tion to patients and using quality control are high in the
diagnosis of OA, for which there is a recent systematic re-
view with a pooled sensitivity of 82% and specificity of 88%.
Peak flow measurements require encouragement and in-
struction of the patient; otherwise at least one third of the
subjects will not produce reliable data [30,31,43,48,56,62-68].
Note: New handheld electronic spirometers storing thewhole flow volume curves and automatically checking for re-
producibility and other quality criteria (e.g. ATS/ERS 2005)
will allow easy quality control and provide additional param-
eters [41]. Their practicability, including the analysis of the
large data set that can result from testing one patient, re-
mains to be shown.
Allergological tests
 The skin prick test (SPT) is the mainstay of
allergological testing. SPT is generally regarded as
sensitive, but with less specificity. The test should be
performed according to international guidelines [69].
Standardized material is rarely available in suspected
occupational allergy cases, but crude extracts produced
locally may be useful. SPT is usually not performed in
low molecular weight (LMW) allergy (with the
exception of platinum salts and reactive dyes).
 Specific immunoglobulin E (IgE) tests are often
less sensitive, but possibly more specific than
SPT. A major shortcoming of allergological tests
is the lack of standardization of most
occupational allergen extracts as well as of the
antibody measuring assays [70-72].
Both SPT and specific IgE tests are in general
sufficiently sensitive for detecting type I
sensitisation and OA caused by most high
molecular weight agents (HMW), but are not
specific for diagnosing asthma [34,73].
Both SPT and specific IgE tests are sensitive for
detecting type I sensitisation and occupational
asthma caused by acid anhydrides and some
reactive dyes, but have a lower specificity for
diagnosing asthma in these cases [74-78]. Skin
prick tests are highly sensitive but less specific for
occupational asthma caused by complex platinum
salts [53,54].
 Other in vitro studies such as mediator release
test (i.e. of histamine) in an allergen-antibody
reaction and release of cytokines during in vitro
stimulation [79] are, to date, not routine tests.Diagnostic methods suitable for specialists in
occupational lung diseases
Specific inhalation challenge tests (SIC) [80,81]. SIC are
commonly regarded as a reference method for diagnos-
ing sensitizer-induced WRA. However, the test is in
practice not well standardized internationally and is
sparsely available [82]. They are subject of a current ERS
taskforce whose preliminary indications are:
 Confirming the diagnosis and cause of OA when
other objective methods are not feasible, have failed
or provide indeterminate results.
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caused by a sensitizing agent when the net potential
clinical benefit of the test is expected to exceed the
risk of complications.
 When a new (not formerly described) specific cause
of OA is suspected.
 For research purposes.
Methods for performance of specific inhalation tests:
These may be performed in a specially designed la-
boratory in two main ways:
1. Controlled laboratory challenge.
By use of this method controlled concentrations of
the suspected sensitizers (standardized allergen
extract) are administered in controlled concentration
and dose either by the inhalation chamber method or
by closed-circuit methodology [81].
Laboratory-based specific challenge testing may
produce false negative results, which has been shown
when comparing laboratory challenge with workplace
challenges which confirmed occupational asthma [83].
2. Workplace challenge test or realistic challenge.
This is an attempt to reproduce actual work
processes and exposures which are performed in line
with the Jack Pepys tradition [84].
The aim of a workplace challenge is to make super-
vised lung function similar to a bronchial provocation
testing in the workplace after suitable control measure-
ments have been made without exposure in the work-
place on separate days. Measurements of NSBHR, cells
in induced sputum, fractional exhaled nitric oxide
(FeNO) etc. can be made in conjunction with the work-
place challenge. The patient should be exposed to the
usual concentrations of the potential causative agent
during the challenge that may last up to 2(−4) hours of
usual exposure. It is important to ensure that the usual
work practices are taking place during the workplace
challenge which may not always be easy to achieve.
Safety considerations are important, and many work-
places do not provide clean and safe environments for
medical treatment and the whole site may be the cause
of the asthma. In these circumstances any emergency
treatment of a severe asthmatic attack would involve re-
moving the worker from the workplace and often from
sources of electrical supply, typically needed to perform
spirometry and operate nebulizers.
Limitations of specific inhalation challenge
Specific bronchial provocation testing can produce
false positive and false negative results. It is particularly
difficult to set up when the exposures are complex (such
as with welding fume or metal working fluid exposures)
or when the process being mimicked involves hightemperatures, explosive or inflammable material. SIC is in
general poorly standardized. Even if the procedure is usu-
ally regarded as the gold standard for diagnosing WRA, it
requires much experience to adequately define the chal-
lenge procedure and to know which parameter to use
when assessing the sensitivity and specificity of this test.
The earliest attempt at assessing the validity of SIC
used continued work with exposure to the original
suspected causative agent without reduction of exposure
for a year. The subsequent absence of deterioration in
asthma was taken as an indicator of no WRA, and the
need for removal from exposure because of repeated se-
vere asthmatic attacks indicated OA. Using these two
criteria, the sensitivity for specific bronchial provocation
testing with isocyanates up to a 30 minute exposure to
0.02 ppm was 82% and for colophony up to a 15 minute
exposure to heating neat colophony was 100%. The rele-
vant specificities were 67% for colophony and 100% for
isocyanate exposure [85].
More recently Rioux [83] performed work place chal-
lenges in 99 workers who had negative specific bronchial
provocation testing but had a good history of OA.
Twenty-nine of these had a positive workplace challenge,
some with subsequent positive bronchial provocation
testing when different agents were tested. Of those who
had negative workplace challenges, 34/70 had asthma or
rhinitis excluded following further investigation. False
negative specific challenges were therefore found in 29/
65 with asthma or rhinitis and a good history of work-
place deterioration [83].
There are no studies evaluating the criteria for a positive
or negative workplace challenge. However, the criteria for
detecting late asthmatic reactions from specific challenges
proposed by Stenton and colleagues [86] are probably ap-
propriate. These criteria specify at least three control days
without exposure, calculating the pooled standard devi-
ation for the FEV1 measurements on the unexposed days
and requiring at least 2 consecutive measurements on the
workplace challenge day to be below these pooled stand-
ard deviation measurements [86]. This method has been
applied to unsupervised serial measurement of PEF and
found to have a specificity of over 90% with specific chal-
lenge testing as the standard [87].
In summary, in spite of their limitations carefully con-
trolled specific challenges come closest to a gold stand-
ard test for some agents causing OA [42,43,49,52].
Further, a negative test in a worker with otherwise good
evidence of OA is not sufficient to preclude the diagno-
sis [42,43,49,52].
Non-invasive methods to assess airway inflammation
Several non invasive methods have been used to assess
and monitor airway inflammation in asthma in the last
decade.
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international committees:
 induced sputum
 exhaled nitric oxide (FeNO)
 exhaled breath condensate (EBC).
Analysis of induced sputum is a valid and reproducible
method for studying airway inflammation [88,89]. The
method consists of inducing sputum production by hav-
ing the patient inhale a hypertonic saline solution. Spu-
tum is subsequently processed and cytospins are
prepared and stained. In addition, inflammatory media-
tors can be measured in sputum supernatant [89]. The
count of eosinophils is the most repeatable parameter in
induced sputum and is a reasonably good non-invasive
index of airway eosinophilia since there is fairly good
agreement between the evaluations of eosinophils in in-
duced sputum, in bronchial biopsy specimens, and in
bronchoalveolar lavage [90]. The validity of this method
is attested to by several studies, which have shown that
sputum inflammatory indices such as eosinophils and
eosinophil cationic protein (ECP) are increased by ex-
posure to common allergens and are reduced with corti-
costeroids [91]. There is evidence that induced sputum
may be useful in clinical practice since evaluation of spu-
tum eosinophils was shown to be equivalent to NSBHR
for discriminating asthma from other conditions, and as-
sessment of sputum eosinophilia improved the manage-
ment of asthma [17,92,93].
Several studies reported sputum eosinophilia in both
early and late reactors between 6 and 24 hours after SIC
in OA caused by both high- and low-molecular weight
occupational agents. Moreover, the addition of sputum
cell counts to monitoring of PEF increased the specifi-
city of this test suggesting that monitoring airway eosin-
ophils in induced sputum improves the diagnosis of OA
[94-96]. Indeed, induced sputum may be useful in the
diagnosis and follow-up of subjects with WRA [97]. Its
utility in epidemiological studies has not been evaluated.
Eosinophil counts in sputum may have other diagnos-
tic uses. Sputum might be helpful in differentiation be-
tween WAA and OA due to a workplace sensitiser that
is superimposed on existing asthma, since two studies
have shown that exposure to occupational agents in
asthmatics not sensitised to the agents did not induce
airway inflammation and did not change the sputum cell
composition [88,98]. The analysis of induced sputum
has also been found to be useful in the identification of
occupational eosinophilic bronchitis. This condition is
characterized by cough on exposure to occupational
agents, without any change in lung function tests [99].
Sputum eosinophilia is not present in all workers with aller-
gic WRA. Compared with those with sputum eosinophilia,those without eosinophilia were exposed to similar agents,
had similar changes in lung function related to work ex-
posure but had less NSBHR [46].
Inhalation of hypertonic saline is not completely non-
invasive, and can cause bronchoconstriction in subjects
with hyperresponsive airways. Its success rate is less than
100%, since some subjects are unable to produce adequate
samples. In addition, the induction is time-consuming and
processing the samples is laborious and needs to be
performed soon after collection [89]. The conclusions from
the ERS evidence-based guidelines was [10];
 Sputum eosinophils increasing by >1% post SIC or
workplace exposure may support a diagnosis of OA
when the FEV1 has fallen <20%.
 The presence or absence of increased sputum
eosinophils is not useful in selecting or excluding
those who might have work-related asthma.
Exhaled nitric oxide (FeNO) is a non-invasive tool for
assessing airway inflammation in asthma [100]. NO is pro-
duced by various cells in the lung either resident or
recruited during the inflammatory process. Exhaled NO is
generally measured on line, the subject blowing directly
into the analyser with immediate results. Portable
analysers are also available. It is also possible to have a re-
mote breath collection into inert bags, with subsequent
analysis. NO concentration is increased in the exhaled air
from patients with asthma and decreased by corticosteroid
therapy [101-103]. There is a positive correlation between
FeNO and sputum eosinophils in asthma [104]. In clinical
practice, evaluation of FeNO was equivalent to sputum
eosinophils in diagnosing asthma [105] and management
of asthma according to FeNO levels was effective to re-
duce maintenance doses of inhaled corticosteroids [106].
Some occupational studies have investigated the role
of FeNO in assessing OA, but with inconsistent results
[98,102,107-112]. It has been suggested that measure-
ment of FeNO can be used to indicate the development
of airway inflammation accompanying late asthmatic re-
actions after SIC in patients with normal or slightly in-
creased basal NO levels [112]. However, the usefulness
of FeNO in the investigation of OA may be limited by
factors affecting its determination, such as therapy with
inhaled steroids and smoking [100]. Although the meas-
urement of FeNO is totally non-invasive, quick and rela-
tively simple to perform, more data are needed to
determine whether FeNO is useful in diagnosing WRA.
 In the clinical setting, a finding of normal exhaled
nitric oxide fraction cannot be used to exclude OA
EBC is collected by cooling or freezing exhaled air and
is also totally non-invasive [113,114]. In addition to
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to detect several volatile and non-volatile chemicals, in-
cluding lipids, proteins and oxidants. Nevertheless, there
are still open questions in the procedure to collect sam-
ples, the reliability of analytical methods for detecting
minute concentrations of chemicals and the expression
of the results. EBC has been used in the investigation of
airway diseases such as asthma, COPD, lung cancer,
interstitial lung disease and acute respiratory distress
syndrome. Since no studies using EBC have been
performed in OA so far, its role in the diagnosis of
WRA remains undetermined.
In summary, the above-mentioned new methods are
promising for monitoring the inflammatory activity in
the airways. However, their definite place in practical
diagnosis is at present not clear.
Diagnosis of diagnostic groups within the
spectrum of WRA
Individual diagnostic steps of the following WRA forms
correspond to the methods mentioned earlier in the sec-
tion on diagnosis of allergic WRA. However, SIC may
produce positive results in spite of negative IgE findings,
e.g. in cases suffering from isocyanate, platinum or irri-
tant asthma with latency (it is clearly inappropriate for
acute irritant induced asthma).
1. Work-aggravated asthma. This is an entity
characterized by symptomatic deterioration of pre-
existing or concomitant non-occupational asthma at
work without a latent interval mainly by irritant
mechanisms. There are similar changes in lung
function related to work exposure as those with
allergen- or irritant-induced OA [115].
2. Irritant-induced asthma [116].
a. Acute irritant induced asthma (Reactive airways
disease syndrome, RADS) [117]. This is a fairly
well described entity. The diagnosis is
retrospective and criteria based, e.g. ACCP
criteria for diagnosis of reactive airway
dysfunction syndrome (RADS) (should meet all
eight) [12]:
1. Documented absence of preceding respiratory
complaints.
2. Onset of symptoms after a single exposure
incident or accident.
3. Exposure to a gas, smoke, fume, or vapor with
irritant properties present in very high
concentration.
4. Onset of symptoms within 24 h after exposure
with persistence of symptoms for at least three
months.
5. Symptoms simulated asthma: cough, wheeze,
dyspnoea.6. Presence of airflow obstruction on pulmonary
function tests (initial testing should be done
shortly after exposure).
7. Presence of nonspecific bronchial
hyperresponsiveness.
8. Other pulmonary diseases ruled out.
b. Not so sudden onset of irritant asthma. As
opposed to RADS this is caused to lower chronic
or repetitive exposures to irritants mostly in the
range of the occupational exposure limits [8,118],
it is commoner in those with atopy or childhood
asthma.
c. Irritant asthma with latency [119]. This is a
controversial entity of asthma defined by
 no prior asthma
 a latent interval from first exposure to disease
 no massive acute exposure
 symptoms related to usual exposure to the
causative agent
 reproducibility of the asthma from either
workplace challenges or specific inhalation
challenge or valid serial measurements of PEF
measurements at and away from work
 an allergic mechanism is very unlikelyDiscussion
The problem of test materials and lack of standardized
technology:
Immunological tests are commonly performed as used
in allergy testing, but the main problem in occupational
allergy is an almost universal lack of standardized re-
quirements for allergy extracts. Simple test may be
performed using material that patients bring to the con-
sultation. For HMW agents close collaboration with an
immunochemist is advisable for optimal characterization
of test material. As regards LMW agents, the problem is
even more complex. For instance, there are more than
thousands different isocyanates compounds known as
yet. In research, most publications deal with monomers
such as toluene diisocyanate, hexamethylenediisocyanate,
methylene diphenyldiisocyanate. However, some patients
may react only with oligomers that are predominantly
used by the industry [120,121]. Furthermore, a new gen-
eration of isocyanates results from the decomposition of
polyurethane coatings or foam during hot work, a
process that can yield irritant toxic agents as well [122].
Collaboration with a qualified chemist is thus necessary
to plan and monitor tests, especially SIC with complex
chemicals.
Situations with conflicting test results
WRA diagnostic efforts may provide conflicting findings,
e.g. the patient may report convincingly work-related
asthmatic symptoms but there are no abnormal findings
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the subject at short intervals including serial FEV1 and
NSBHR monitoring is recommended in such situations.
An accelerated FEV1 decline can be detected statistically
using the Spirola program [123].
Conclusions
The potential health benefit of a correct and early diag-
nosis of WRA is considerable both for the individual, in-
dustry and society. However, the possibility of WRA is
frequently not considered by the doctor and adequate
measures to secure an etiologic diagnosis are not
performed. Organized collaboration between occupa-
tional, primary care and specialized centre physicians is
required to improve the situation. An integrated ap-
proach is recommended [71].
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